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Stereotactic radiosurgery is a relatively recent radiation technique initially developed using a frame-
based system in 1949 by a Swedish neurosurgeon, Lars Leksell, for lesions not amendable to surgical
resection. Radiosurgery is founded on principles of extreme radiation dose escalation, afforded
by precise dose delivery with millimeter to submillimeter accuracy. Building upon the success of
frame-based radiosurgery techniques, which were limited to cranial tumors and invasive head-
frame placement, advances in radiation delivery and image guidance have led to the development
of stereotactic body radiotherapy (SBRT). SBRT allows for frameless delivery of dose distributions
akin to frame-based cranial stereotactic radiosurgery to both cranial and extracranial sites and has
emerged as an important treatment strategy for a variety of cancers from the cranium to prostate.
In this research topic, we present a compendium of scientific papers that highlight the forefront
of clinical applications of SBRT. This collection of papers showcase the wide application of SBRT for
primary cancers often in patient populations in whom conventional treatment strategies are either
not possible anatomically, fraught with risk due to medical comorbidities, or present significant
threats to patient quality of life. This includes the primary treatment for elderly patients with
inoperable head and neck cancers, medically inoperable early-stage non-small cell lung cancer,
adrenal metastases, and early-stage organ confined prostate cancer. Through stereotaxy, SBRT
limits the volume of tissue that is irradiated which is especially important when considering
reirradiation for recurrent tumors; this is highlighted through the collection with papers discussing
SBRT for reirradiation of primary brain tumors, skull-base, and parenchymal brain metastases, and
gynecologic tumors. Finally, as a number of papers herein highlight, SBRT both due to its short
overall treatment time, minimal acute side effects, and unique underlying radiobiological effects,
holds the potential for integration with novel systemic therapies aimed at improving outcomes and
even potentially engaging the immune system in the oncologic armamentarium. This collection
could, thus, serve as an invaluable resource for the growing breadth of SBRT application as physicians
continue the relentless pursuit of tackling some of the most challenging cases in oncology.
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